228 related articles for article (PubMed ID: 27371157)
1. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial.
Barch DM; Marder SR; Harms MP; Jarskog LF; Buchanan RW; Cronenwett W; Chen LS; Weiss M; Maguire RP; Pezous N; Feuerbach D; Lopez-Lopez C; Johns DR; Behrje RB; Gomez-Mancilla B
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():66-75. PubMed ID: 27371157
[TBL] [Abstract][Full Text] [Related]
2. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.
Feuerbach D; Pezous N; Weiss M; Shakeri-Nejad K; Lingenhoehl K; Hoyer D; Hurth K; Bilbe G; Pryce CR; McAllister K; Chaperon F; Kucher K; Johns D; Blaettler T; Lopez Lopez C
Br J Pharmacol; 2015 Mar; 172(5):1292-304. PubMed ID: 25363835
[TBL] [Abstract][Full Text] [Related]
3. Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia.
Tregellas JR; Olincy A; Johnson L; Tanabe J; Shatti S; Martin LF; Singel D; Du YP; Soti F; Kem WR; Freedman R
Neuropsychopharmacology; 2010 Mar; 35(4):938-42. PubMed ID: 19956085
[TBL] [Abstract][Full Text] [Related]
4. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers.
Loughead J; Ray R; Wileyto EP; Ruparel K; Sanborn P; Siegel S; Gur RC; Lerman C
Biol Psychiatry; 2010 Apr; 67(8):715-21. PubMed ID: 20207347
[TBL] [Abstract][Full Text] [Related]
5. The effect of long-term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls--a randomized placebo-controlled, double-blind fMRI study.
Guse B; Falkai P; Gruber O; Whalley H; Gibson L; Hasan A; Obst K; Dechent P; McIntosh A; Suchan B; Wobrock T
Behav Brain Res; 2013 Jan; 237():300-7. PubMed ID: 23022750
[TBL] [Abstract][Full Text] [Related]
6. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
7. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.
George MS; Molnar CE; Grenesko EL; Anderson B; Mu Q; Johnson K; Nahas Z; Knable M; Fernandes P; Juncos J; Huang X; Nichols DE; Mailman RB
Schizophr Res; 2007 Jul; 93(1-3):42-50. PubMed ID: 17467956
[TBL] [Abstract][Full Text] [Related]
8. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B
Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766
[TBL] [Abstract][Full Text] [Related]
9. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.
Tregellas JR; Tanabe J; Rojas DC; Shatti S; Olincy A; Johnson L; Martin LF; Soti F; Kem WR; Leonard S; Freedman R
Biol Psychiatry; 2011 Jan; 69(1):7-11. PubMed ID: 20728875
[TBL] [Abstract][Full Text] [Related]
10. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI).
Dunbar GC; Inglis F; Kuchibhatla R; Sharma T; Tomlinson M; Wamsley J
J Psychopharmacol; 2007 Mar; 21(2):171-8. PubMed ID: 17329297
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
[TBL] [Abstract][Full Text] [Related]
12. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
[TBL] [Abstract][Full Text] [Related]
14. Initial phase 2 trial of a nicotinic agonist in schizophrenia.
Freedman R; Olincy A; Buchanan RW; Harris JG; Gold JM; Johnson L; Allensworth D; Guzman-Bonilla A; Clement B; Ball MP; Kutnick J; Pender V; Martin LF; Stevens KE; Wagner BD; Zerbe GO; Soti F; Kem WR
Am J Psychiatry; 2008 Aug; 165(8):1040-7. PubMed ID: 18381905
[TBL] [Abstract][Full Text] [Related]
15. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults.
Potter AS; Dunbar G; Mazzulla E; Hosford D; Newhouse PA
Biol Psychiatry; 2014 Feb; 75(3):207-14. PubMed ID: 23856296
[TBL] [Abstract][Full Text] [Related]
16. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
Preskorn SH; Gawryl M; Dgetluck N; Palfreyman M; Bauer LO; Hilt DC
J Psychiatr Pract; 2014 Jan; 20(1):12-24. PubMed ID: 24419307
[TBL] [Abstract][Full Text] [Related]
17. Effects of aripiprazole and haloperidol on neural activation during the n-back in healthy individuals: A functional MRI study.
Goozee R; Reinders AATS; Handley R; Marques T; Taylor H; O'Daly O; McQueen G; Hubbard K; Mondelli V; Pariante C; Dazzan P
Schizophr Res; 2016 Jun; 173(3):174-181. PubMed ID: 25778615
[TBL] [Abstract][Full Text] [Related]
18. Acute caffeine administration impact on working memory-related brain activation and functional connectivity in the elderly: a BOLD and perfusion MRI study.
Haller S; Rodriguez C; Moser D; Toma S; Hofmeister J; Sinanaj I; Van De Ville D; Giannakopoulos P; Lovblad KO
Neuroscience; 2013 Oct; 250():364-71. PubMed ID: 23876323
[TBL] [Abstract][Full Text] [Related]
19. Initial Cross-Over Test of A Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers With Or Without Schizophrenia.
Perkins KA; Roy Chengappa KN; Karelitz JL; Boldry MC; Michael V; Herb T; Gannon J; Brar J; Ford L; Rassnick S; Brunzell DH
Neuropsychopharmacology; 2018 May; 43(6):1334-1342. PubMed ID: 29185480
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
Beinat C; Banister SD; Herrera M; Law V; Kassiou M
CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
